Previous close | 81.84 |
Open | 87.36 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 87.08 - 87.37 |
52-week range | 87.08 - 87.37 |
Volume | 600 |
Avg. volume | N/A |
Market cap | 15.859B |
Beta (5Y monthly) | 0.71 |
PE ratio (TTM) | 19.10 |
EPS (TTM) | 4.56 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN).
Benchmarks declined from record highs on Monday as investors weighed impact of rise in coronavirus cases and ongoing political turmoil on economic growth.
BioMarin (BMRN) announces one-year update from GENEr8-1 phase III study, which shows that valoctocogene roxaparvovec significantly reduces annualized bleeding rate (ABR) by 84% in patients with hemophilia A.